Table 4.
Correlation of clinicopathological characteristics with NSD1 expression in patients with PDA
| Characteristic | Estimate for increase NSD1 score a |
SE | p value |
|---|---|---|---|
| Tumour site: head vs body/tail | −24.8 | 18.9 | 0.194 |
| Jaundice | 7.04 | 14.3 | 0.624 |
| Weight loss | 14.4 | 13.3 | 0.284 |
| Abdominal pain | −13.8 | 12.8 | 0.286 |
| Preoperative diabetes | −20.1 | 16.0 | 0.215 |
| BMI (kg/m2) | −0.44 | 1.16 | 0.704 |
| Smoking (pack-years) | 0.24 | 0.31 | 0.434 |
| Alcohol use: heavy vs low/moderate | −16.8 | 20.8 | 0.421 |
| Serum CA19-9 | −0.0013 | 0.0044 | 0.761 |
| Total bilirubin | −0.11 | 0.94 | 0.905 |
| Alkaline phosphatase | −0.0022 | 0.0124 | 0.861 |
| Tumour size | −7.8 | 4.4 | 0.080 |
| Clinical stage (AJCC8) | |||
| Overall difference | 0.022 b | ||
| Stage III/IV vs stage I/IIA | 46.0 | 17.3 | 0.026 b |
| Stage IIB vs stage I/IIA | 15.1 | 15.8 | 0.605 |
| Stage III/IV vs stage IIB | 30.9 | 13.9 | 0.076 |
| Tumour grade | |||
| Overall difference | 0.038 b | ||
| G1 vs G2 | −31.4 | 17.0 | 0.070 |
| G1 vs G3 | 1.8 | 18.5 | 0.924 |
| G2 vs G3 | 33.2 | 14.1 | 0.022 b |
| Lymph node metastases present | 20.0 | 13.9 | 0.155 |
| Perineural invasion present | 9.7 | 12.7 | 0.447 |
| Angiolymphatic invasion present | −5.9 | 12.7 | 0.642 |
| Common bile duct extension present | −7.3 | 13.0 | 0.573 |
| Peripancreatic extension present | −25.5 | 17.1 | 0.142 |
| Duodenal extension present | 0.9 | 12.7 | 0.945 |
| Neoadjuvant treatment | 34.6 | 16.2 | 0.037 b |
a
Estimate of effect for increase in NSD1 score.
b
p<0.05.
AJCC8, American Joint Committee on Cancer 8th edition cancer staging manual; BMI, body mass index; CEA, carcinoembryonic antigen; PDA, pancreatic ductal adenocarcinoma; SE, standard error.